← Back to patent-cliff list
ITM-14D
Tier C — Watch / tradeITM-14D
ITM Radiopharmazie Munchen GmbH
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：SSTR
Indications (approved)：Pancreatic neuroendocrine tumour
Regional status
US
-
EU
Phase III
2024-05-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of ITM-14D?
Approved indications include: Pancreatic neuroendocrine tumour.
When does the ITM-14D patent expire?
No public expiry year is available for ITM-14D yet; this page updates once verified.
How do I get a quote for ITM-14D intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01